Drug interactions
Darifenacin + Glimepiride-pioglitazone
Severity: Minor
Darifenacin and Glimepiride-pioglitazone: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Darifenacin is a weak CYP3A4 and CYP2D6 inhibitor with little expected effect on pioglitazone, which relies mainly on CYP2C8. No meaningful clinical interaction is expected.
What this interaction means in plain words
Darifenacin and Glimepiride-pioglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Darifenacin belongs to Genitourinary; Glimepiride-pioglitazone belongs to Endocrine.
Why it happens
Theoretical weak CYP3A4 inhibition affecting a minor pioglitazone metabolic pathway.
What to do
No adjustment is needed; routine glycemic monitoring is sufficient.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Darifenacin and Glimepiride-pioglitazone, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Glimepiride-pioglitazone
Other interactions of Darifenacin
Frequently asked questions
Can I take Darifenacin with Glimepiride-pioglitazone?
MediHelp rates the interaction as minor. Darifenacin and Glimepiride-pioglitazone have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Darifenacin is a weak CYP3A4 and CYP2D6 inhibitor with little expected effect on pioglitazone, which relies mainly on CYP2C8. No meaningful clinical interaction is expected.
How serious is the interaction between Darifenacin and Glimepiride-pioglitazone?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No adjustment is needed; routine glycemic monitoring is sufficient.
What other medicines interact with Glimepiride-pioglitazone?
MediHelp also lists interactions of Glimepiride-pioglitazone with, for example, Fluconazole, Gemfibrozil, Insulin aspart. The full list is on the Glimepiride-pioglitazone page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
